Literature DB >> 10726935

Vaccine characteristics and acceptability of HIV immunization among adolescents.

G D Zimet1, M J Blythe, J D Fortenberry.   

Abstract

HIV immunization programmes will only be effective if sufficient numbers of persons accept the vaccine. Our aims were to evaluate HIV vaccine acceptability among adolescents and to examine how vaccine characteristics influence acceptability. We recruited 661 adolescents from community health clinics in Indianapolis, Indiana, USA to complete either written or computerized questionnaires, both of which assessed HIV vaccine acceptability as a function of efficacy, cost, type of vaccine, mode of delivery, and parental permission for immunization (required or not required). For both the written and computer methods, efficacy had the strongest effect on acceptability, followed by type of vaccine and cost. Low efficacy, high cost, and live-attenuated vaccines were associated with lower acceptability. These findings suggest that as efforts to develop HIV vaccines continue, it will be important, in parallel, to anticipate potential obstacles to vaccine acceptance, including the belief that a less efficacious HIV vaccine is unacceptable.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10726935     DOI: 10.1258/0956462001915570

Source DB:  PubMed          Journal:  Int J STD AIDS        ISSN: 0956-4624            Impact factor:   1.359


  15 in total

1.  Using an integrated approach to understand vaccination behavior among young men who have sex with men: stages of change, the health belief model, and self-efficacy.

Authors:  Scott D Rhodes; Kenneth C Hergenrather
Journal:  J Community Health       Date:  2003-10

2.  Vaginal microbicide preferences among midwestern urban adolescent women.

Authors:  Amanda E Tanner; Jennifer M Katzenstein; Gregory D Zimet; Dena S Cox; Anthony D Cox; J Dennis Fortenberry
Journal:  J Adolesc Health       Date:  2008-06-05       Impact factor: 5.012

3.  What can HIV vaccine trials teach us about future HIV vaccine dissemination?

Authors:  Peter A Newman; Naihua Duan; Lisa Kakinami; Kathleen Roberts
Journal:  Vaccine       Date:  2008-03-28       Impact factor: 3.641

4.  Barriers to adolescents' participation in HIV biomedical prevention research.

Authors:  Ralph J DiClemente; Monica S Ruiz; Jessica McDermott Sales
Journal:  J Acquir Immune Defic Syndr       Date:  2010-07       Impact factor: 3.731

5.  HIV vaccine acceptability among communities at risk: the impact of vaccine characteristics.

Authors:  Peter A Newman; Naihua Duan; Sung-Jae Lee; Ellen T Rudy; Danielle S Seiden; Lisa Kakinami; William E Cunningham
Journal:  Vaccine       Date:  2005-11-21       Impact factor: 3.641

6.  How can we communicate about vaccines with adolescents and their parents?

Authors:  Andrea L Benin; Ann C Wu; Eric S Holmboe; Eugene D Shapiro; Walter Anyan
Journal:  Clin Pediatr (Phila)       Date:  2010-01-28       Impact factor: 1.168

7.  Development of an HIV vaccine attitudes scale to predict HIV vaccine acceptability among vulnerable populations: L.A. VOICES.

Authors:  Sung-Jae Lee; Peter A Newman; Naihua Duan; William E Cunningham
Journal:  Vaccine       Date:  2014-07-18       Impact factor: 3.641

Review 8.  Factors influencing familial decision-making regarding human papillomavirus vaccination.

Authors:  Heather L Gamble; James L Klosky; Gilbert R Parra; Mary E Randolph
Journal:  J Pediatr Psychol       Date:  2009-12-04

9.  Use of conjoint analysis to assess HIV vaccine acceptability: feasibility of an innovation in the assessment of consumer health-care preferences.

Authors:  S J Lee; P A Newman; W S Comulada; W E Cunningham; N Duan
Journal:  Int J STD AIDS       Date:  2012-04       Impact factor: 1.359

10.  Analysis of hepatitis B vaccination behavior and vaccination willingness among migrant workers from rural China based on protection motivation theory.

Authors:  Rugang Liu; Youwei Li; Knut R Wangen; Elizabeth Maitland; Stephen Nicholas; Jian Wang
Journal:  Hum Vaccin Immunother       Date:  2016-04-14       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.